Marjoram for Hormonal Balance and PCOS

This is the most interesting page on marjoram, and it rests on one small study. That sentence is the whole article in miniature, and we want it at the top rather than buried under enthusiasm.

In 2016, a research group in Jordan published a randomized, placebo-controlled crossover trial in which women with polycystic ovary syndrome drank sweet marjoram tea (Origanum majorana) twice a day for a month. Compared with a matched placebo tea, the marjoram period was associated with improved insulin sensitivity and a reduction in DHEA-S, an androgen made by the adrenal glands. The paper is Haj-Husein, Tukan and Alkazaleh, The effect of marjoram (Origanum majorana) tea on the hormonal profile of women with polycystic ovary syndrome: a randomised controlled pilot study, in the Journal of Human Nutrition and Dietetics.

That is a genuinely well-designed study of a cheap, safe, pleasant intervention in a condition where women are frequently offered very little. It is also a pilot: a few dozen participants at most, one month of exposure, blood markers rather than symptoms or outcomes, and — nearly a decade on — no published replication. Both halves of that assessment are true at the same time, and this page tries to hold them together instead of picking whichever half makes a better headline.

Table of Contents

1. What PCOS Actually Is
2. The Trial: How It Was Built
3. What It Reported
4. What It Cannot Tell Us
5. Insulin Sensitivity: Why This Is the Real Story
6. DHEA-S and the Adrenal Side of PCOS
7. Plausible Mechanisms
8. The Spearmint Precedent
9. Where Marjoram Sits Among Real PCOS Treatments
10. Menstrual Pain and the Emmenagogue Tradition
11. How to Use It, If You Decide To
12. Safety, Pregnancy and Interactions
13. Key Research Papers
14. Connections

What PCOS Actually Is

Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, and it is badly named — the cysts are not really cysts, and plenty of women with the syndrome do not have them. What defines it is a cluster: irregular or absent ovulation, clinical or biochemical excess of androgens (acne, unwanted hair growth, scalp hair thinning, or raised androgen levels on a blood test), and often polycystic-appearing ovaries on ultrasound. Diagnosis conventionally requires two of the three, with other causes excluded.

Two engines drive most of it. The first is insulin resistance: the body's cells respond poorly to insulin, the pancreas compensates by producing more, and high circulating insulin drives the ovary to make more androgen while also suppressing the liver protein (sex hormone-binding globulin) that would otherwise keep androgens bound and inactive. Less binding protein means more free, biologically active testosterone from the same total. The second engine is a disturbed pituitary signalling pattern that further pushes ovarian androgen production.

Understanding the insulin engine is what makes the marjoram finding interesting rather than random. Insulin resistance is not a side effect of PCOS — for many women it is upstream of the whole picture, which is why metformin, an insulin-sensitising drug, is a mainstay of treatment and why weight change, activity and diet quality have such disproportionate effects. Any intervention that plausibly improves insulin sensitivity is pulling on the right lever. Whether marjoram tea pulls hard enough to matter is exactly the open question.

The Trial: How It Was Built

Evidence tier: randomized clinical trial (pilot).

The design deserves credit, because a lot of herbal research does not bother with any of it.

• Randomized and placebo-controlled. Participants were allocated by chance, and the comparison was a placebo tea rather than no treatment — important when the intervention is a warm drink with an aroma and a ritual attached.
• Crossover. Each participant took both the marjoram tea and the placebo tea in sequence, so every woman served as her own control. In a small study this is a real strength: it removes the between-person variability that otherwise swamps a tiny sample. It also means the sample size does less work than it would in a parallel-group design — a mitigating factor, not a cure.
• Blinded. The teas were prepared to be as indistinguishable as practical. Blinding an aromatic herb against a placebo is genuinely difficult and is a fair place to keep some scepticism, since marjoram smells distinctly of marjoram.
• Duration: one month of twice-daily tea per phase.
• Participants: women with diagnosed PCOS, in a small pilot-scale group — on the order of a couple of dozen. For the exact number, group allocation and washout arrangement, read the paper; we deliberately do not restate precise figures we cannot verify against the original text.
• Outcomes: blood measures of glucose metabolism and of the hormones relevant to PCOS — insulin sensitivity indices and androgens.

Nothing about this is sloppy. It is a properly conducted small trial that its own authors labelled a pilot — that is, a study designed to find out whether a bigger study is worth running, not to answer the clinical question.

What It Reported

Two findings carried the paper.

1. Improved insulin sensitivity

During the marjoram phase, indices of insulin sensitivity improved relative to placebo. These are calculated measures — derived from fasting glucose and fasting insulin — that estimate how efficiently insulin is working. They are the standard, practical way to assess insulin sensitivity outside a research laboratory, and they are also indirect estimates rather than direct measurements of glucose disposal.

2. Reduced DHEA-S

Dehydroepiandrosterone sulfate (DHEA-S) is an androgen produced by the adrenal cortex. It fell during the marjoram phase. In PCOS, roughly a quarter to a third of women have an adrenal contribution to their androgen excess on top of the ovarian one, and DHEA-S is the marker that captures it. A tea that moves it is doing something specific rather than generic.

What was not the headline

The findings the paper foregrounds are those two. Notably, a large improvement in the androgen most directly responsible for the symptoms women actually report — free testosterone, the fraction driving acne and hair changes — is not what made this study famous. If you want to know precisely which hormone measures moved and by how much, and which did not reach statistical significance, read the paper's own results tables. We are not going to paraphrase numbers we cannot verify, because on this site paraphrased numbers have gone wrong before.

What It Cannot Tell Us

Five limitations, each of which independently prevents this from being a settled result.

1. Size. A pilot of a couple of dozen participants can detect only large effects, and small trials systematically overstate the effects they do find. This is one of the most reliable patterns in clinical research: when a small positive trial is followed by a large one, the effect usually shrinks, sometimes to nothing. Expecting the marjoram effect to be smaller than reported is the statistically literate default, not cynicism.
2. Duration. One month. PCOS is a lifelong condition managed over years. A month tells you a marker can move; it says nothing about whether it stays moved, whether the body adapts, or whether anything clinically meaningful follows.
3. Surrogate endpoints. The trial measured blood markers, not outcomes. It did not show restored ovulation, more regular periods, improved fertility, less acne or hair growth, weight change, or reduced long-term risk of type 2 diabetes. Those are what women with PCOS actually want, and the study did not measure them. Surrogate markers moving in the right direction is encouraging; the history of medicine is full of surrogate markers that moved beautifully while patients got no better.
4. No replication. This is the big one. A single positive pilot is a hypothesis. Nearly a decade later there is still no independent trial of marjoram tea in PCOS. The PubMed search for marjoram and PCOS is short enough that you can check this yourself in a minute, and we would encourage you to.
5. Blinding of an aromatic tea. Marjoram has an unmistakable smell. However carefully the placebo was matched, some participants may have worked out which phase they were in, and expectation influences self-reported outcomes far more than blood chemistry — which is, incidentally, a mild argument in favour of taking the biochemical findings more seriously than any subjective ones.

Insulin Sensitivity: Why This Is the Real Story

If any part of the marjoram finding turns out to be durable, this is the part that would matter most, so it is worth understanding why.

In PCOS, high insulin is not just a metabolic nuisance sitting alongside the hormonal problem — it is often causing it. Insulin acts directly on ovarian theca cells to increase androgen output, and it suppresses hepatic production of sex hormone-binding globulin, which raises the free fraction of whatever testosterone is present. Lower the insulin and you pull on both threads at once: less ovarian drive, more binding capacity, less free androgen. That is the mechanism through which weight loss, exercise and metformin all produce hormonal improvements without ever touching a hormone.

It is also why the long game in PCOS is metabolic. Women with PCOS carry substantially elevated lifetime risk of type 2 diabetes, gestational diabetes and metabolic syndrome. Insulin sensitivity is not a laboratory abstraction; it is the variable that decides much of the next thirty years.

Which sets up the honest verdict. A cheap, safe tea that nudges insulin sensitivity would be a welcome addition to a metabolic strategy. But “addition” is the operative word. The interventions with large, replicated effects on insulin sensitivity in PCOS are physical activity, dietary quality, sleep, modest weight loss where relevant, and metformin. Marjoram tea, on current evidence, is a plausible garnish on that plan. It is not one of the load-bearing elements, and treating it as one would be a real cost — because the load-bearing elements are the ones that actually change outcomes.

DHEA-S and the Adrenal Side of PCOS

DHEA-S is worth a section because it is the finding people skip past, and it is arguably the more novel one.

Androgen excess in PCOS has two sources. The ovary is the main one. But a substantial minority of women also have an adrenal contribution, and DHEA-S — produced almost entirely by the adrenal cortex, circulating at high concentration with a long half-life — is the cleanest single marker of it. Because it is stable through the day, it is also one of the more reliable androgen measurements you can take, unlike testosterone, which fluctuates.

Clinically, adrenal-predominant androgen excess tends to respond less well to treatments aimed at the ovary. So an intervention that moves DHEA-S is targeting a real gap. What is unknown is how: nobody has shown whether marjoram affects adrenal steroid synthesis directly, acts through the pituitary signal that drives the adrenal cortex, alters the enzymes that interconvert androgens in peripheral tissue, or simply follows along behind the insulin change. Until somebody looks, the DHEA-S result is a real observation without a mechanism.

One practical caution. DHEA-S is also a diagnostic test: a markedly raised level is a red flag for congenital adrenal hyperplasia or an androgen-secreting tumour, not for PCOS. Drinking a tea that may lower it while an undiagnosed cause goes unexamined is a bad trade. Get the workup first.

Plausible Mechanisms

Evidence tier: preliminary and speculative.

The trial did not investigate mechanism, so what follows is hypothesis. We are flagging it as such because this is exactly the point at which health writing usually starts asserting things.

• Phenolic effects on glucose handling. Marjoram is rich in rosmarinic acid and related phenolics — Roby and colleagues quantified this in Evaluation of antioxidant activity, total phenols and phenolic compounds in thyme (Thymus vulgaris L.), sage (Salvia officinalis L.), and marjoram (Origanum majorana L.) extracts (Industrial Crops and Products, 2013). Dietary polyphenols as a class have been studied for effects on carbohydrate-digesting enzymes, glucose transport and insulin signalling. This is the most conventional explanation available and requires no marjoram-specific magic.
• Reduced oxidative and inflammatory load. Insulin resistance in PCOS is accompanied by low-grade inflammation and oxidative stress, and there is a plausible causal loop between them. An antioxidant-dense infusion could in principle interrupt it. Marjoram's antioxidant capacity is thoroughly documented in vitro — see Erenler and colleagues, Isolation and identification of chemical constituents from Origanum majorana and investigation of antiproliferative and antioxidant activities (Journal of the Science of Food and Agriculture, 2016) — though in vitro antioxidant capacity is a notoriously poor predictor of anything in a person.
• Direct effects on steroid-metabolising enzymes. Various plant flavonoids inhibit enzymes in the steroid pathway (aromatase and the 17β-hydroxysteroid dehydrogenases among them) in laboratory systems. Marjoram contains luteolin- and apigenin-type flavones, which appear in that literature. Whether anything like this happens at tea-strength concentrations in a human adrenal gland is entirely unknown.
• The infusion effect. Replacing two sweetened drinks a day with an unsweetened herbal tea would itself improve insulin sensitivity. A crossover placebo-tea design controls for this well — both phases were tea — and it is a good example of why the design mattered.

The Spearmint Precedent

Evidence tier: randomized clinical trials, different plant.

Marjoram's PCOS trial did not appear out of nowhere. It followed a small but real line of work on another mint-family tea.

Grant published Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial in Phytotherapy Research in 2010, following Akdoğan and colleagues' Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism in the same journal in 2007. Both reported that spearmint tea lowered androgen measures in women with androgen-excess conditions.

Two things follow. First, the marjoram trial was a reasonable hypothesis rather than a shot in the dark: a chemically related Lamiaceae infusion had already produced a signal. Second — and this is the sobering part — spearmint has been in this literature since 2007 and still has not accumulated the trial base to become a recommended treatment. Its results were also small, also short, and also thinly replicated. That is the realistic trajectory for a herbal tea finding: not disproof, but a long plateau of promise. Marjoram is roughly nine years behind spearmint on the same road.

Where Marjoram Sits Among Real PCOS Treatments

Placing it honestly is more respectful of your time than praising it.

• Strong, replicated evidence: physical activity and dietary change; modest weight reduction where there is excess weight; metformin for the metabolic and ovulatory picture; combined hormonal contraceptives for cycle control and androgenic symptoms; letrozole for ovulation induction when fertility is the goal; anti-androgens such as spironolactone for hirsutism; inositol supplements, which have a real if debated randomized-trial base for insulin sensitivity and ovulation.
• Modest or contested evidence: inositol dosing specifics, vitamin D repletion where deficient, N-acetylcysteine, berberine for the metabolic component — each with some trials and real uncertainty.
• One small pilot: marjoram tea.

That is not a reason to avoid marjoram tea. It is a reason to place it correctly: a pleasant, near-zero-risk addition to a plan whose real work is done elsewhere. If drinking it makes you feel engaged in managing your own condition, that is a genuine and underrated benefit. If it becomes a reason to postpone an endocrinology appointment, it has cost you something that no tea can repay.

Menstrual Pain and the Emmenagogue Tradition

Evidence tier: randomized clinical trial of a blend, plus traditional use.

Marjoram has a second, older hormonal reputation: as an emmenagogue, a plant used to bring on or regulate menstruation. This tradition is well attested and is the direct source of the pregnancy caution repeated throughout this site — a plant with a reputation for stimulating menstruation is not one to take in medicinal quantity while pregnant. Note carefully what that means as evidence: the tradition supports the caution, not the efficacy. No controlled study has tested whether marjoram affects menstrual timing at all.

There is one relevant piece of human trial data, and it is topical rather than internal. Ou and colleagues published Pain relief assessment by aromatic essential oil massage on outpatients with primary dysmenorrhea: a randomized, double-blind clinical trial in the Journal of Obstetrics and Gynaecology Research in 2012. Women with painful periods massaged the lower abdomen with a carrier oil containing lavender, clary sage and marjoram essential oils; the aromatic blend outperformed the plain carrier oil for pain.

The value and the limitation are the same fact: it was a blend, and marjoram was one of three oils. Lavender has by far the largest independent trial base of the three, so it is the most likely primary contributor. A positive blend result cannot be divided among its components. What it does support is a low-risk, non-drug option for period pain — abdominal massage with a diluted aromatic oil — without licensing any claim about marjoram specifically.

How to Use It, If You Decide To

There is no established therapeutic dose of marjoram for anything. The only regimen ever tested in humans is the trial's, so it is the only sensible model:

• Preparation: a covered infusion of dried sweet marjoram — roughly a teaspoon per cup of just-boiled water, steeped five to ten minutes, then strained. Cover the cup; the aromatic oils leave with the steam.
• Schedule: twice daily, which is what the trial used.
• Duration: the trial ran a month. If you are going to judge whether it does anything for you, give it at least that.
• Verify the species. Buy something labelled Origanum majorana or “sweet marjoram”. “Wild marjoram” is oregano and was not what was studied; “pot marjoram” is usually a different Origanum as well.
• Not the essential oil. The trial used tea. Marjoram essential oil is not a concentrated version of the trial — distillation leaves the water-soluble phenolics behind entirely, so it is a chemically different preparation, and it should not be swallowed.
• Track something real. If you use it, use it as an experiment: note your cycle, your energy, your skin, and if you are having bloods done anyway, note the numbers before and after. A tea whose only effect is on a marker you never measure is not doing you any observable good.

Safety, Pregnancy and Interactions

Marjoram tea is about as low-risk as a botanical intervention gets. The cautions that exist are real but narrow.

• Pregnancy — avoid medicinal doses. This matters especially here, because many women with PCOS are actively trying to conceive. Marjoram in food is fine. Twice-daily therapeutic tea, extracts and the essential oil should be stopped if you are pregnant or may be, on the strength of the emmenagogue tradition described above. The tradition is untested in both directions, and pregnancy is the wrong place to resolve an open question. Discuss it with your obstetric or fertility provider.
• Anticoagulants — theoretical. Aromatic Lamiaceae herbs contain constituents that affect platelet behaviour in laboratory conditions, and dried marjoram contributes vitamin K, which is directly relevant to warfarin control. No bleeding events have been documented from marjoram. If you take warfarin, a direct oral anticoagulant or antiplatelet therapy, keep intake steady rather than variable and tell whoever manages your dosing.
• Diabetes and insulin-sensitising medication. If the insulin-sensitivity finding is real, marjoram tea could in principle add to metformin or other glucose-lowering agents. The likely magnitude is small, but if you take insulin or a sulfonylurea — drugs that can cause genuine hypoglycaemia — monitor when you start, and mention it at your next review.
• Hormonal medication. There is no evidence that marjoram tea interferes with combined contraceptives, anti-androgens or fertility treatment. There is also no study looking, so if you are on ovulation induction or an anti-androgen, tell your prescriber what you are drinking.
• Allergy. Rare; relevant if you know you react to mint-family herbs.

Key Research Papers

Citations are live PubMed searches rather than numeric identifiers, with title, journal and year given so you can confirm the paper.

1. Randomized clinical trial (pilot) — Haj-Husein I, Tukan S, Alkazaleh F. The effect of marjoram (Origanum majorana) tea on the hormonal profile of women with polycystic ovary syndrome: a randomised controlled pilot study. Journal of Human Nutrition and Dietetics, 2016. The study this entire page is about. Read it yourself for the exact sample size and results tables. Search PubMed
2. Review — Bina F, Rahimi R. Sweet Marjoram: A Review of Ethnobotany, Phytochemistry, and Pharmacology. Journal of Evidence-Based Complementary & Alternative Medicine, 2017. Places the PCOS trial in the context of everything else known about O. majorana. Search PubMed
3. Randomized clinical trial, related plant — Grant P. Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytotherapy Research, 2010. The precedent that made the marjoram hypothesis reasonable. Search PubMed
4. Clinical trial, related plant — Akdoğan M, et al. Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. Phytotherapy Research, 2007. The earlier spearmint work. Search PubMed
5. Randomized clinical trial, marjoram-containing blend — Ou MC, et al. Pain relief assessment by aromatic essential oil massage on outpatients with primary dysmenorrhea: a randomized, double-blind clinical trial. Journal of Obstetrics and Gynaecology Research, 2012. Lavender, clary sage and marjoram in carrier oil for period pain. Search PubMed
6. Preliminary (in vitro) — Roby MHH, et al. Evaluation of antioxidant activity, total phenols and phenolic compounds in thyme (Thymus vulgaris L.), sage (Salvia officinalis L.), and marjoram (Origanum majorana L.) extracts. Industrial Crops and Products, 2013. Quantifies the rosmarinic-acid-rich fraction proposed as the active principle. Search PubMed
7. Preliminary (in vitro) — Erenler R, et al. Isolation and identification of chemical constituents from Origanum majorana and investigation of antiproliferative and antioxidant activities. Journal of the Science of Food and Agriculture, 2016. Individual marjoram constituents and their activity. Search PubMed
8. Preliminary (chemistry) — Vera RR, Chane-Ming J. Chemical composition of the essential oil of marjoram (Origanum majorana L.) from Reunion Island. Food Chemistry, 1999. Why marjoram oil is not oregano oil. Search PubMed
9. Open topic search — the replication question, answerable in one minute: marjoram and PCOS, everything indexed
10. Open topic search — the interventions with the real evidence base, for comparison: inositol in PCOS and metformin and insulin sensitivity in PCOS
11. Open topic search — the adrenal androgen question: DHEA-S and adrenal androgen excess in PCOS

Back to Table of Contents

Connections

• All Herbs
• Marjoram — the main page: botany, chemistry, culinary use.
• Marjoram Benefits Deep Dive — hub for all four evidence reviews.
• Sleep, Mood and Pain — the aromatherapy blend trials, including the dysmenorrhea study.
• Digestive Health — the older and more traditional use.
• PCOS — the condition, its diagnosis and its evidence-based management.
• Polycystic Ovary Syndrome — extended coverage of the syndrome.
• Insulin Resistance — the engine the marjoram finding touches.
• Metabolic Syndrome — the long-term risk cluster PCOS overlaps.
• Type 2 Diabetes — the outcome insulin sensitivity ultimately predicts.
• Endocrinology — all hormonal conditions on this site.
• Chasteberry — the other herb most often used for menstrual and hormonal complaints.
• Berberine — the herbal compound with the most metabolic trial data relevant to PCOS.
• Cinnamon — another kitchen spice studied for insulin sensitivity.
• Fenugreek — culinary seed with glucose-related research.
• Gymnema — traditional blood-sugar herb, with its own evidence limits.
• Black Cohosh — a hormonally studied herb with a very different risk profile.
• Dong Quai — traditional gynaecological herb, and its anticoagulant caution.
• Chromium — mineral studied for insulin sensitivity.
• Magnesium — relevant to insulin resistance and widely under-consumed.

Safety and disclaimer. This article is educational and is not medical advice. PCOS is a medical diagnosis with real long-term metabolic and fertility consequences, and it needs proper assessment and management — marjoram tea is not a treatment for it, and the single pilot trial described here does not make it one. Avoid medicinal doses of marjoram in pregnancy or when trying to conceive without discussing it with your provider; be cautious and consistent if you take anticoagulants; monitor if you take glucose-lowering medication. Never ingest marjoram essential oil. Talk to a doctor, endocrinologist or registered dietitian before adding any herb to the management of a diagnosed condition.

Back to Table of Contents